Malignancies

• CLINICAL_TRIALS trial_result · 2026-06-03
  Clinical Trial Update: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies [Phase 3]

  Phase 3 trial updating results for tislelizumab, pamiparib, and other investigational agents in participants with advanced malignancies.

• CLINICAL_TRIALS research · 2024-10-30
  Clinical Trial Update: Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors [EARLY_Phase 1]

  An early-phase (Phase 1) trial is evaluating a dual-targeting CAR-T therapy against HER2 and PD-L1 for solid tumors, including metastatic pe…

• CLINICAL_TRIALS trial_result · 2024-02-06
  Clinical Trial Update: A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating AZD7648 alone and in combination with other anti-cancer agents in patients with advanced malignancies …

• CLINICAL_TRIALS trial_result · 2023-12-06
  Clinical Trial Update: Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies [Phase 1, Phase 2]

  Phase I/II study of MBG453 alone and with PDR001 in advanced malignancies; trial terminated with posted results.

• CLINICAL_TRIALS trial_result · 2022-09-27
  Clinical Trial Update: A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies [Phase 1, Phase 2]

  Phase 1/2 trial evaluating INCAGN01949 in combination with immune therapies for advanced or metastatic malignancies has completed with resul…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-10-14
  Clinical Trial Update: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]

  Phase 1 study of oral PF-02341066 (crizotinib) as a tyrosine kinase inhibitor targeting c-Met/HGF pathway in advanced cancers; study complet…

• CLINICAL_TRIALS trial_result · 2021-07-22
  Clinical Trial Update: INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies [Phase 1, Phase 2]

  Phase 1/2 trial of INCAGN01876 in combination with immune therapies in advanced/metastatic cancers was terminated; results posted in 2021.

• CLINICAL_TRIALS trial_result · 2021-02-26
  Clinical Trial Update: A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

  Phase 1/2 clinical trial update for INCAGN01876 in advanced or metastatic solid tumors; study completed with results posted.

• CLINICAL_TRIALS trial_result · 2020-12-21
  Clinical Trial Update: A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread [Phase 1]

  Phase 1 trial evaluating cabiralzumab alone or with nivolumab in advanced malignancies; study completed with results posted.

• CLINICAL_TRIALS trial_result · 2020-04-17
  Clinical Trial Update: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies [Phase 1, Phase 2]

  Open-label phase 1/2 trial of the JAK inhibitor INCB052793 in patients with advanced solid tumors; study terminated with results posted in 2…

• CLINICAL_TRIALS trial_result · 2019-03-15
  Clinical Trial Update: A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies [Phase 1]

  Phase I study of MLN8237 (Aurora A kinase inhibitor) in adults with advanced malignancies; results posted.

• CLINICAL_TRIALS trial_result · 2019-03-14
  Clinical Trial Update: A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors [Phase 1]

  Phase 1 trial of MLN8237 (Aurora A kinase inhibitor) in participants with advanced solid tumors completed; results posted.

• CLINICAL_TRIALS trial_result · 2018-02-20
  Clinical Trial Update: The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. [Phase 4]

  Phase 4 clinical trial evaluating whether a PET/CT imaging agent (18F-ALF-NOTA-PRGD2) can predict efficacy and adverse events of apatinib in…